Cancer Research UK presents charity collection in collaboration with influencer Shannon Alexandra at the Love Not Landfill fashion pop-up in London.

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

From snowy days in the country to festive wreaths and stockings, the shop has a design to suit every taste.

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

In the last 6 years, almost 55,000 cancer patients should have been diagnosed or started their treatment sooner, according to new calculations.

Patients taking the drug trastuzumab deruxecan were 72% less likely to see their cancer grow significantly or to die than those on an existing breast cancer treatment.

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

Pembrolizumab will be made available for some adults in Scotland with bowel cancer that’s spread to other parts of the body.